PRAGUE 14: Anti-thrombotic therapy before non-cardiac surgery may be associated with a higher incidence of bleeding.

The majority of coronary patients are under anti-thrombotic therapy and its interruption may increase cardiovascular risk, while on the other hand, continuation during a surgical procedure may increase the risk of bleeding.

This study, which included 1211 patients who underwent non-cardiac surgery, compared the interruption of anti-thrombotic therapy at least 7 days prior vs continuing the therapy.

The majority of the patients (83.7%) were receiving anti-thrombotic therapy within one month of the surgery and the most frequent drug was aspirin (53.3%), followed by Warfarin, 23.4%.

The incidence of cardiovascular complications was 7.6% and perioperative bleeding, 13.3%. Of those who presented cardiovascular complications, 37.4% died compared with 1.26% of those who bled.

Conclusion: 

This study showed that the interruption of anti-thrombotic therapy closer to surgery is not associated with the reduced risk of cardiovascular complications in the general population. 

P.%20Widimsky_slides
P. Widimsky
2013-09-02

Original title: PRAGUE 14: Perioperative ischemia versus perioperative bleeding in consecutive cardiac patients undergoing non-cardiac surgery.

More articles by this author

INTIME: Home monitoring of severe heart failure patients gives promising results.

Rehospitalization or death due to worsening heart failure is often preceded by changes in clinical parameters, weight or arrhythmias. The home monitoring device has...

DECAAF: Pre ablation magnetic resonance in patients with atrial fibrillation is capable of detecting the degree of fibrosis and predicting the success of...

260 patients with atrial fibrillation were included who underwent nuclear magnetic resonance 30 days before ablation and 90 days following. The patients were classified...

LINC: The LUCAS device failed to demonstrate benefit in cardiac arrest patients.

Each year between 300,000 and 400,000 people suffer an out-of-hospital heart attack in Europe. Only between 5% and 7% of these patients survive and...

PARIS: Interruption of dual antiplatelet treatment can be safe depending on the clinical context and treatment time

The cessation of dual antiplatelet treatment increased the risk of post coronary intervention adverse events. It is unclear whether the risk varies through time...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....